Skip to content
AnalystLens

CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Apr 23, 2024)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed April 23, 2024
Period End
April 23, 2024
Security
CAH
In the record · 2016–202610-K1110-Q328-K120

CAH filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Aug ’20Aug ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed April 23, 2024. Cited figures are marked; the original filing is the authoritative source.

On April 23, 2024, Cardinal Health furnished voluntary, unaudited recast segment results under its new reporting structure, effective in the third quarter of fiscal 2024.

The company consolidated its prior segments into two reportable segments, Pharmaceutical and Specialty Solutions (PSS) and Global Medical Products and Distribution (GMPD). Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics are reported as Other. The filing states that the recast is not a restatement and does not change previously reported consolidated revenue, operating earnings, net earnings, or diluted EPS.

Its effect is limited to segment presentation, including changes to inter-segment revenue eliminations and the allocation of shared corporate expenses. The recast data shows that PSS is the dominant and growing business. PSS revenue reached $188.8 billiona in fiscal 2023, up 15% from fiscal 2022, and grew 12% in Q2 fiscal 2024 with $53.2 billion of quarterly revenue.

Its fiscal 2024 year-to-date segment profit was $961 millionb, up 15% on a year-over-year basis. GMPD revenue has been declining, falling 8% to $12.2 billion in fiscal 2023, and it has been loss-making at the segment level, with a fiscal 2023 segment loss of $162 million. Its first-half fiscal 2024 segment result was roughly breakeven, a clear improvement from the prior-year first half.

Total segment profit rose 29% year-to-date in fiscal 2024, to $1.17 billionc, driven mainly by PSS and the GMPD turnaround. For investors, the key takeaway is that the new structure gives clearer visibility into the core pharmaceutical distribution engine and into the progress of the medical products business. Because the filing reports only unaudited segment data and does not update guidance or consolidated financials, investors should treat the recast as a basis for future segment comparisons rather than as new information about overall profitability.

02—Key points

Key Highlights

  1. Cardinal Health moved to two reportable segments, PSS and GMPD, with Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics reported as Other, effective Q3 fiscal 2024.
  2. The recast is explicitly not a restatement. Consolidated revenue, operating earnings, net earnings, and diluted EPS for all prior periods are unchanged.
  3. PSS dominates the business, with fiscal 2023 segment revenue of $188.8 billion (about 92% of total segment revenue) and fiscal 2024 year-to-date revenue of $103.9 billion, up 12%.
  4. PSS segment profit reached $961 million in the first half of fiscal 2024, up 15% year over year, and fiscal 2023 segment profit was $1.86 billion.
  5. GMPD revenue fell 8% to $12.2 billion in fiscal 2023, but its first-half fiscal 2024 segment result (about -$2 million) improved sharply from roughly -$129 million in the prior-year first half.
  6. Total segment profit rose 29% to $1.17 billion in the first half of fiscal 2024, with Q2 fiscal 2024 up 22% year over year.
  7. The recast changes inter-segment revenue eliminations and the allocation of shared corporate expenses. For example, former Pharmaceutical segment profit would have been $10 million lower in fiscal 2023 and $13 million lower in fiscal 2022, with offsetting increases to the former Medical segment.

03—Questions

Frequently Asked Questions

  1. Does the segment recast change Cardinal Health's reported consolidated financial results?

    No. The company states that the unaudited recast segment results are not a restatement and do not affect previously reported consolidated revenue, operating earnings/(loss), net earnings/(loss), or diluted EPS for any prior period. The changes only affect how revenue and profit are distributed across segments.

  2. What are Cardinal Health's new reportable segments?

    The two reportable segments are Pharmaceutical and Specialty Solutions (PSS) and Global Medical Products and Distribution (GMPD). Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics are not individually significant enough to be reportable and are grouped under Other.

  3. Why did Cardinal Health change its segment structure?

    The company says the change is part of its simplification efforts, intended to prioritize core operational execution, drive efficiency, and improve accountability and transparency. The new structure took effect in the third quarter of fiscal 2024.

  4. How is the business performing under the new segment structure?

    PSS is the main growth engine, with revenue up 12% in the first half of fiscal 2024 and segment profit up 15%. GMPD revenue has been declining but its segment loss has narrowed to about breakeven in the first half of fiscal 2024, a significant improvement from the prior-year period. Total segment profit rose 29% year to date.

  5. Will investors see different numbers going forward?

    Yes. The company will prepare its financial results on the basis of the updated structure beginning in the third quarter of fiscal 2024, so future segment disclosures will follow the new two-segment and Other presentation. This filing does not provide updated guidance or changes to consolidated figures.

04—Continue

← View all 8-K filings